TY - JOUR
T1 - Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy
T2 - ASCO Endorsement of College of American Pathologists Guideline
AU - Vikas, Praveen
AU - Messersmith, Hans
AU - Compton, Carolyn
AU - Sholl, Lynette
AU - Broaddus, Russell R.
AU - Davis, Anjee
AU - Estevez-Diz, Maria
AU - Garje, Rohan
AU - Konstantinopoulos, Panagiotis A.
AU - Leiser, Aliza
AU - Mills, Anne M.
AU - Norquist, Barbara
AU - Overman, Michael J.
AU - Sohal, Davendra
AU - Turkington, Richard C.
AU - Johnson, Tyler
N1 - Publisher Copyright:
© 2023 American Society of Clinical Oncology.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - PURPOSEThe College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.METHODSThe CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations.RESULTSThe ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.RECOMMENDATIONSWithin the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines.
AB - PURPOSEThe College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.METHODSThe CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations.RESULTSThe ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.RECOMMENDATIONSWithin the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85149831285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149831285&partnerID=8YFLogxK
U2 - 10.1200/JCO.22.02462
DO - 10.1200/JCO.22.02462
M3 - Article
C2 - 36603179
AN - SCOPUS:85149831285
SN - 0732-183X
VL - 41
SP - 1943
EP - 1948
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -